Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine

Vaccine

Volumn 29, Issue 45, 2011, Pages 8066-8072

  Atmar, Robert L ^a   Keitel, Wendy A ^a   Quarles, John M ^b   Cate, Thomas R ^a   Patel, Shital M ^a   Nino, Diane ^a   Wells, Janet ^a   Arden, Nancy ^b   Guo, Kuo ^c   Hill, Heather ^c   Couch, Robert B ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS A M COLLEGE OF MEDICINE   (United States)

^c EMMES CORPORATION   (United States)

Author keywords

H9N2; Immunogenicity; Inactivated vaccine; Influenza; Priming

Indexed keywords

INFLUENZA VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG FEVER; DRUG INDUCED HEADACHE; ERYTHEMA; FEMALE; GROUPS BY AGE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA; INFLUENZA A (H9N2); INFLUENZA A H9N2; INFLUENZA VIRUS A H9N2; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; NAUSEA; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGE FACTORS; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H9N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 80053623553     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.044     Document Type: Article

References (24)

1. Choi Y.K., Ozaki H., Webby R.J., Webster R.G., Peiris J.S., Poon L., et al. Continuing evolution of H9N2 influenza viruses in Southeastern China. J Virol 2004, 78:8609-8614.
2. Lee Y.J., Shin J.Y., Song M.S., Lee Y.M., Choi J.G., Lee E.K., et al. Continuing evolution of H9 influenza viruses in Korean poultry. Virology 2007, 359:313-323.
3. Butt K.M., Smith G.J., Chen H., Zhang L.J., Leung Y.H., Xu K.M., et al. Human infection with an avian H9N2 influenza A virus in Hong Kong in 2003. J Clin Microbiol 2005, 43:5760-5767.
4. Peiris M., Yuen K.Y., Leung C.W., Chan K.H., Ip P.L., Lai R.W., et al. Human infection with influenza H9N2. Lancet 1999, 354:916-917.
5. World Health Organization. Responding to the avian influenza pandemic threat. Recommended strategic actions. Pamphlet no. WHO/CDS/CSR/GIP/2005.8, Geneva: World Health Organization; 2005.
6. Atmar R.L., Keitel W.A., Patel S.M., Katz J.M., She D., El Sahly H., et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 2006, 43:1135-1142.
7. Hehme N., Engelmann H., Kunzel W., Neumeier E., Sanger R. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol (Berl) 2002, 191:203-208.
8. Karron R.A., Callahan K., Luke C., Thumar B., McAuliffe J., Schappell E., et al. A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. J Infect Dis 2009, 199:711-716.
9. Nicholson K.G., Thompson C.I., Klap J.M., Wood J.M., Batham S., Newman R.W., et al. Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations. Vaccine 2009, 28:171-178.
10. Stephenson I., Nicholson K.G., Gluck R., Mischler R., Newman R.W., Palache A.M., et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 2003, 362:1959-1966.
11. Dowdle W.R., Kendal A.P., Noble G.R. Influenza viruses. Diagnostic procedures for viral, rickettsial, and chlamydial infections 1979, 585-609. American Public Health Association, Washington (DC). 5 ed. E.H. Lennette, N.J. Schmidt (Eds.).
12. Frank A.L., Puck J., Hughes B.J., Cate T.R. Microneutralization test for influenza A and B and parainfluenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement. J Clin Microbiol 1980, 12:426-432.
13. Keitel W.A., Atmar R.L., Cate T.R., Petersen N.J., Greenberg S.B., Ruben F., et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006, 166:1121-1127.
14. Couch R.B. Seasonal inactivated influenza virus vaccines. Vaccine 2008, 26(Suppl. 4):D5-D9.
15. Okuno Y., Isegawa Y., Sasao F., Ueda S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 1993, 67:2552-2558.
16. Wang T.T., Tan G.S., Hai R., Pica N., Ngai L., Ekiert D.C., et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A 2010, 107:18979-18984.
17. Corti D., Suguitan A.L., Pinna D., Silacci C., Fernandez-Rodriguez B.M., Vanzetta F., et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 2010, 120:1663-1673.
18. Dormitzer P.R., Galli G., Castellino F., Golding H., Khurana S., Del Giudice G., et al. Influenza vaccine immunology. Immunol Rev 2011, 239:167-177.
19. Chen H., Subbarao K., Swayne D., Chen Q., Lu X., Katz J., et al. Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate. Vaccine 2003, 21:1974-1979.
20. Lu X., Renshaw M., Tumpey T.M., Kelly G.D., Hu-Primmer J., Katz J.M. Immunity to influenza A H9N2 viruses induced by infection and vaccination. J Virol 2001, 75:4896-4901.
21. Langley J.M., Frenette L., Ferguson L., Riff D., Sheldon E., Risi G., et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis 2010, 201:1644-1653.
22. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370:580-589.
23. Leroux-Roels I., Bernhard R., Gerard P., Drame M., Hanon E., Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 2008, 3:e1665.
24. Stephenson I., Bugarini R., Nicholson K.G., Podda A., Wood J.M., Zambon M.C., et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005, 191:1210-1215.